In particular, the mAbs such as anti‐SLAMF7 mAb elotuzumab, and anti‐CD38 mAb daratumumab, function in part by facilitating antibody‐dependent cellular cytotoxicity (ADCC) of natural killer (NK) cells,4, 5 highlighting a pivotal role of NK cells in immune surveillance against MM. Here, SLAMF7 is linked to Miyoshi myopathy.